Regeneron Dupixent Registry Eosinophilic Esophagitis EoE_Leiman - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the long-term effectiveness of an approved medicine that is prescribed for the treatment of EoE. We want to know how will dupilumab (Dupixent®) works over time when EoE patients and their doctors choose it as therapy. Dupilumab was approved by the FDA in May 2022 to treat EoE and was the first drug approved for this purpose.

What is the Condition Being Studied?

Esofagitis eosinofílica (EE)

Who Can Participate in the Study?

Adults ages 18+ who plan to start using dupilumab as a long-term therapy for EoE.

For more information, contact the study team at nicole.pavlus@duke.edu.

Grupo etario

Adultos

What is Involved?

If you choose to join this study, you will give us permission to collect information from your routine doctor visits to manage your EoE. Additionally, you will have research "check-ins" with the study team approximately every 3 months for the first 6 months, and then every 6 months thereafter to answer questionnaires. You will be in the study for up to 3 years (36 months).